85006-25-3 Usage
Description
TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE, also known as N,O-Di-Boc-hydroxylamine (N,O-Bis(tert-butoxycarbonyl)hydroxylamine), is a chemical compound that serves as a versatile intermediate in the synthesis of various organic compounds. It is characterized by its ability to protect the hydroxyl and amine groups during chemical reactions, allowing for selective functionalization of other groups in the molecule.
Uses
Used in Pharmaceutical Industry:
TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE is used as a synthetic intermediate for the development of pharmaceutical compounds. Its ability to protect hydroxyl and amine groups makes it a valuable component in the synthesis of complex organic molecules, including drug candidates.
Used in Synthesis of 5-Lipoxygenase Inhibitor LY280810:
In the pharmaceutical industry, TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE is used as a key intermediate in the synthesis of LY280810, a potent 5-lipoxygenase inhibitor. TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE has potential applications in the treatment of inflammatory diseases by inhibiting the production of leukotrienes, which are involved in the inflammatory process.
Used in Synthesis of Hydroxylamines:
TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE is used as a starting material for the synthesis of hydroxylamines, which are important intermediates in the production of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Synthesis of Hydroxamic Acids:
In the field of organic chemistry, TERT-BUTYL N-(TERT-BUTOXYCARBONYLOXY)CARBAMATE is used as a precursor in the synthesis of hydroxamic acids. These compounds have a wide range of applications, including as chelating agents, inhibitors of metalloenzymes, and in the development of pharmaceuticals targeting various biological targets.
Synthesis Reference(s)
Journal of the American Chemical Society, 81, p. 955, 1959 DOI: 10.1021/ja01513a049Tetrahedron Letters, 34, p. 7043, 1993 DOI: 10.1016/S0040-4039(00)61592-7
Check Digit Verification of cas no
The CAS Registry Mumber 85006-25-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,0,0 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 85006-25:
(7*8)+(6*5)+(5*0)+(4*0)+(3*6)+(2*2)+(1*5)=113
113 % 10 = 3
So 85006-25-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H19NO5/c1-9(2,3)14-7(12)11-16-8(13)15-10(4,5)6/h1-6H3,(H,11,12)
85006-25-3Relevant articles and documents
A Facile Synthesis of N,O-bis(tert-butoxycarbonyl)-Hydroxylamine
Staszak, Michael A.,Doecke, Christopher W.
, p. 7043 - 7044 (1993)
N,O-bis(tert-butoxycarbonyl)hydroxylamine was synthesized in 85percent yield from hydroxylamine hydrochloride and di-tert-butyl dicarbonate in the presence of triethylamine.The chemistry is facile, utilizes readily available reagents and represents an improvement in safety over the previously published method.
Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming
Pasini, Alice,Marchetti, Chiara,Sissi, Claudia,Cortesi, Marilisa,Giordano, Emanuele,Minarini, Anna,Milelli, Andrea
supporting information, p. 1218 - 1223 (2017/12/26)
A series of hybrid compounds was designed to target histone deacetylases and ds-/G-quadruplex DNAs by merging structural features deriving from Scriptaid and compound 1. Compound 6 binds different DNA arrangements, inhibits HDACs both in vitro and in cells, and is able to induce a reduction of cell proliferation. Moreover, compound 6 displays cell phenotype-reprogramming properties since it prevents the epithelial to mesenchymal transition in cancer cells, inducing a less aggressive and migratory phenotype, which is one of the goals of present innovative strategies in cancer therapies.
BACE INHIBITORS
-
Page/Page column 19, (2014/05/24)
The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -CH3, or -OCH3; and R4 is H or F; or a pharmaceutically acceptable salt thereof.
